A University of Florida study published in Nature Metabolism links the popular joint supplement glucosamine to a 25% increased risk of mild cognitive impairment progressing to dementia, as well as a 25% higher mortality risk in patients already diagnosed with Alzheimer's. While laboratory tests in mice and human brain tissues suggest glucosamine may fuel an overactive protein sugar-tagging pathway, medical experts emphasize the findings are observational, do not prove causation, and should not prompt patients to abruptly stop taking the supplement without consulting a physician.
Study findings on glucosamine risks
- ▪The University of Florida study found that glucosamine use among patients already diagnosed with Alzheimer's disease and related dementias was associated with a 25% higher mortality risk.
- ▪A University of Florida study published in Nature Metabolism linked the use of the joint supplement glucosamine with a 25% increased risk of mild cognitive impairment progressing to dementia.
- ▪The University of Florida study found no association between glucosamine use and mortality risk in patients with mild cognitive impairment.
Methodology of the health record analysis
- ▪The electronic health record analysis included 2,750 patients with mild cognitive impairment and 1,896 patients with Alzheimer's disease and related dementias who reported using glucosamine.
- ▪University of Florida researchers analyzed deidentified electronic health records from UF Health spanning 2012 to 2024 using artificial intelligence methods.
Biological mechanisms of glucosamine
- ▪Glucosamine can cross the blood-brain barrier and enter biochemical pathways involved in O-GlcNAcylation, a cellular process where sugar molecules attach to proteins.
- ▪In genetically modified Alzheimer's model mice, glucosamine administration increased cellular protein sugar-tagging and worsened social memory deficits, which subsequently improved when the sugar-attachment pathway was chemically suppressed.
- ▪University of Florida researchers found that the protein sugar-tagging system was excessively active in human Alzheimer's disease brain tissue supplied by the UF Neuromedicine Brain and Tissue Bank.
Limitations and need for further research
- ▪Study co-author Dr. Matt Gentry stated that the electronic health record findings raise a provocative clinical question that warrants deeper investigation into how supplements interact with brain health.
- ▪Medical experts, including Dr. Nupur Rajoriya and Dr. Anandh Balasubramaniam, emphasize that the retrospective study is observational and does not prove that glucosamine causes or accelerates dementia in humans.
- ▪Researchers state that a controlled human clinical trial is required to determine whether glucosamine directly causes faster cognitive decline or if other confounding factors explain the health record association.
Expert advice and caveats for patients
- ▪Dr. Nupur Rajoriya notes that the study's US-based healthcare data may not be directly applicable to Indian populations due to differences in genetics, lifestyle, diet, and healthcare access.
- ▪Dr. Nupur Rajoriya advises that patients currently taking glucosamine should not discontinue the supplement abruptly without consulting their physician.
Debatable claims
- ▪Patients with mild cognitive impairment should stop taking glucosamine
- ▪US-based health record studies are sufficient to guide medical advice in other countries
Story comments
Loading comments…